Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Small Molecules

Mighty Morphin’ Small Molecules

Polymorphism is a well-established phenomenon whereby chemical compounds exist in multiple crystalline forms. These forms can differ in terms of solubility, melting point, and other basic properties, which can affect the bioavailability of drugs. Naturally, controlling polymorphism is of interest to pharma developers – the more forms chemists can produce, the greater the possibilities. 

Researchers from the University of Montreal, Canada, have uncovered a method of searching for polymorphs based on mixed-crystal seeds (1). Using the approach, the team produced new crystalline forms of the small molecule ROY – which is used to synthesize antipsychotic drug Olanzapine.   

“The method promises to become a valuable tool for polymorphic screening in all fields where crystalline solids are used,” according to the authors. Meanwhile, Susan Reutzel-Edens, a senior research advisor at Eli Lilly, has reportedly said the platform is “likely to see widespread use across the pharmaceutical industry” (2).

Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

  1. A Levesque, T Maris and J D Wuest, “ROY Reclaims Its Crown: New Ways To Increase Polymorphic Diversity” (2020). Available at: https://bit.ly/30GbdfX 
  2. C&EN, “New methods to control small molecule crystallization” (2020). Available at: https://bit.ly/3imWNqH 

About the Author

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register